The risk of Down syndrome (Down syndrome, CRSD) is a concern for expectant parents and doctors during pregnancy. This syndrome is one of the most common chromosomal abnormalities and can affect the development of the child. Prenatal screening, including hormonal panels and biochemical analysis, has become an extremely important tool for determining the individual risk of CRSD during the first trimester of pregnancy.<\/p>\n
Before considering prenatal screening, it is important to understand what Down syndrome is. It is a genetic condition that results from having an extra copy of chromosome 21. Down syndrome can lead to a variety of medical problems and psychological challenges in a child, including developmental delays and intellectual disabilities.<\/p>\n
Prenatal screening for Down syndrome risk in the first trimester aims to provide parents with more information about the possible risk and to determine whether further diagnostics, such as chorionic villus sampling or amniocentesis, which are usually associated with greater risks to the pregnancy, are necessary.<\/p>\n
The main methods of prenatal screening for determining the risk of Down syndrome in the first trimester are a hormonal panel and a biochemical analysis. The hormonal panel involves measuring the levels of two hormones: beta-chorionic gonadotropin (hCG) and progesterone in the mother's blood. This data, together with the mother's age, weight, and other factors, is used to calculate the risk of Down syndrome.<\/p>\n